Stanford Scientists Regrow Cartilage, Halt Arthritis Progression

A study led by Stanford Medicine researchers has‍ found that an injection blocking a protein linked to aging can reverse the natural loss of knee cartilage in older mice. The same treatment also stopped⁤ arthritis from developing after knee injuries that resemble ACL tears,which are common among athletes and recreational exercisers. Researchers note that an oral version of the‍ treatment is ⁣already being tested in clinical trials aimed at treating age-related muscle weakness.

Human cartilage samples taken from knee replacement surgeries also responded positively. Thes samples included both the supportive extracellular matrix of the joint and cartilage-producing chondrocyte cells. When treated, the tissue began forming new, functional cartilage.

Together, the findings suggest that cartilage lost due to aging or arthritis may one day be restored using ⁤either a pill or a⁢ targeted injection. If triumphant in people, ⁢such treatments could reduce or even eliminate the need for knee and hip replacement surgery.

A Direct Attack on ⁤osteoarthritis

Osteoarthritis is a degenerative joint disease that affects about one in five adults in the United States and generates an estimated ⁢$65 ⁣billion each year in direct health care ⁤costs. Current ⁢treatments focus on managing pain or replacing damaged joints surgically.There are no approved drugs that can slow or reverse the ⁣underlying cartilage damage.

The new approach targets the root ⁤cause of the disease rather than its symptoms, offering a potential shift in how osteoarthritis is treated.

The Role of a Master Aging Enzyme

The protein at the center of the study is called 15-PGDH. Researchers refer to it as a gerozyme because its levels increase as the body⁢ ages. gerozymes were identified by the ⁢same ‍research team in 2023 and are known to drive the gradual loss of tissue function.

In mice, higher levels of 15-PGDH are linked to declining muscle strength with age. Blocking the enzyme using a ⁣small molecule boosted muscle mass and endurance ⁣in older animals. In contrast, forcing ⁢young mice to produce more 15-PGDH caused their muscles to⁤ shrink and weaken. The ⁢protein has ⁢also been connected‍ to regeneration in bone, nerve, and blood cells.

In most of these tissues, repair happens through the activation and⁤ specialization of stem cells. Cartilage appears to be different. In this case, chondrocytes change how their genes behave, shifting into a more youthful state without relying on stem cells.

A New Path to Tissue Regeneration

“This⁢ is ⁤a new way of regenerating adult tissue,and it has notable clinical promise for treating⁣ arthritis due to aging or ⁤injury,” said Helen Blau,PhD,professor of microbiology and immunology.”We were looking for stem cells, but they are clearly not involved. It’s very exciting.”

Blau, who leads the‍ Baxter Laboratory for Stem Cell Biology and holds the Donald E. and Delia⁢ B. Baxter Foundation Professorship, and Nidhi Bhutani, PhD, associate professor of orthopaedic surgery, are the study’s senior‍ authors. The research was published in Science. Mamta Singla, PhD, instructor of orthopaedic surgery,⁤ and former postdoctoral scholar Yu Xin (Will) Wang, PhD, served as⁢ led authors. wang is now an assistant professor at the Sanford Burnham Institute in San Diego.

Dramatic Regeneration of Joint Cartilage

“Millions of people suffer from joint pain and swelling as they age,” Bhutani said. “It is a huge unmet medical need. Until now, there has been no drug that directly treats the cause of cartilage loss. but this⁢ gerozyme inhibitor causes a dramatic regeneration ⁣of cartilage beyond that reported in response to any ⁤other drug or intervention.”

The human body contains three main types of cartilage. Elastic cartilage is soft and flexible and forms structures such as⁤ the outer ear. fibrocartilage is dense‍ and tough, helping absorb shock in places like the spaces between spinal vertebrae.Hyaline cartilage is smooth and glossy, allowing joints such as the hips, knees, shoulders, and ankles to move with low⁤ friction. This type, also called articular cartilage, is the form ⁢most commonly damaged in osteoarthritis.

Why cartilage

Research Shows Potential for cartilage Regeneration Through 15-PGDH Inhibition

This report details research suggesting a novel approach to cartilage regeneration by inhibiting the enzyme 15-PGDH.The findings, stemming‍ from studies in mice and human cartilage samples, indicate a potential pathway to reverse ‍cartilage degradation and promote tissue repair without relying on stem or progenitor cells.

Key Findings from Animal Studies

Research conducted on mice demonstrated significant shifts in⁣ gene expression within cartilage tissue following treatment ⁣with a‍ 15-PGDH ‍inhibitor. Specifically:

* Genes associated with cartilage degradation and those ⁢promoting fibrocartilage formation decreased. Degradation-related ⁢genes dropped from 8% to 3%, while the fibrocartilage group declined from 16% to 8%.
* A population of cells shifted towards a profile characteristic of hyaline ‍cartilage ⁣formation and extracellular matrix maintenance, increasing from 22%⁣ to 42%.
* These changes suggest a reversion to a more youthful⁣ cartilage ⁢profile.

Human Cartilage Sample Results

Further investigation ‍using cartilage samples from patients undergoing total knee ⁣replacement for osteoarthritis showed promising results after one week of treatment with ⁢the 15-PGDH inhibitor:

* A reduction in the number ⁢of 15-PGDH-producing⁢ chondrocytes.
* Decreased expression of‍ genes linked to cartilage ⁣degradation and fibrocartilage formation.
* ‍Early indications of articular cartilage regeneration.

15-PGDH ⁢Inhibition and Tissue Regeneration

Researchers, including Dr. Nidhi Bhutani, believe the ⁣mechanism is significant, highlighting the ability of existing cartilage cells to alter their gene expression patterns. This suggests a potential for⁣ broader clinical impact by targeting these cells for regeneration.

Clinical Trial Outlook

Stanford University and Epirium Bio are pursuing clinical trials.

Phase 1 clinical trials evaluating a 15-PGDH inhibitor for muscle weakness ⁤have already demonstrated safety and activity in healthy volunteers. Plans are underway to launch a similar trial focused on cartilage regeneration. Dr. Helen Blau expressed ⁤optimism about the potential to regrow existing cartilage ⁢and avoid the need for joint replacement surgery.

Funding and Potential Conflicts of Interest

The research ⁣was supported by grants from the National institutes of Health (R01AR070864, R01AR077530, R01AG069858 and R00NS120278), the Baxter Foundation for ⁢Stem ‍Cell Biology, the Li Ka ‍Shing Foundation, the Stanford Cardiovascular Institute, the Milky Way⁣ Research Foundation, the Canadian Institutes of Health Research, a Stanford Translational Research and applied Medicine Pilot grant, a GlaxoSmithKline Sir James Black Postdoctoral Fellowship, and a Stanford Dean’s postdoctoral Fellowship.

It is noted that Blau, Bhutani, and other co-authors hold ⁣patent applications related to 15-PGDH inhibition and‍ have financial ties to Myoforte/Epirium Bio. Blau is a co-founder and holds equity in the company.

Verification Status⁣ (as of 2026/01/21 12:31:36):

As of⁣ the date of this response, there have been ‍no major, publicly available updates regarding the initiation of Phase ⁣2 ‍clinical trials for 15-PGDH inhibitors in cartilage regeneration beyond the stated intention to launch a trial. A search of ⁤clinical trial registries (e.g.,⁢ clinicaltrials.gov) using keywords “15-PGDH,” “cartilage regeneration,” and “osteoarthritis” does not reveal any trials initiated after the publication of this research.The information regarding⁢ Phase 1 trials for muscle ⁢weakness remains consistent ⁣with publicly available data. The funding sources ⁣and conflict of interest ⁢disclosures are consistent with information available on the stanford University and Epirium ‍Bio websites.